Pr
Non vérifié

ProMIS Neurosciences Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologiePhotographiePublicité/Marketing/Médias/Communication
16/11/2026
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
1.00
12/11/2026
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
1.00
05/11/2026
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences to Participate in Upcoming Conferences in November
1.00
06/10/2026
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
1.00
13/08/2026
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
1.00
13/07/2026
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
1.00
12/05/2026
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
1.00
25/03/2026
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0